Evidence map›Paper›PMID 39891136›Full record

ArticleBMC cancer2025

First molecules to reactivate RAS

Aneta Wlodarczyk, Cezary Treda, Marcin Pacholczyk, Adrianna Rutkowska, Marta Wegierska, Amelia Kierasinska-Kalka, Katarzyna Wasiak, Damian Ciunowicz, Dagmara Grot, Pawel Glowacki and 2 more

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aneta WlodarczykDepartment of Research and Development, Personather, LTD, Inwestycyjna 7 St, Konstantynow Lodzki, 95-050, Poland. aneta.wlodarczyk@umed.lodz.pl.
Cezary TredaDepartment of Research and Development, Personather, LTD, Inwestycyjna 7 St, Konstantynow Lodzki, 95-050, Poland.
Marcin PacholczykDepartment of Tumor Biology, Chair of Medical Biology, Medical University of Lodz, Zeligowskiego 7/9 St, Lodz, 90- 752, Poland.
Adrianna RutkowskaDepartment of Research and Development, Personather, LTD, Inwestycyjna 7 St, Konstantynow Lodzki, 95-050, Poland.
Marta WegierskaDepartment of Research and Development, Personather, LTD, Inwestycyjna 7 St, Konstantynow Lodzki, 95-050, Poland.
Amelia Kierasinska-KalkaDepartment of Research and Development, Personather, LTD, Inwestycyjna 7 St, Konstantynow Lodzki, 95-050, Poland.
Katarzyna WasiakDepartment of Research and Development, Personather, LTD, Inwestycyjna 7 St, Konstantynow Lodzki, 95-050, Poland.
Damian CiunowiczDepartment of Research and Development, Personather, LTD, Inwestycyjna 7 St, Konstantynow Lodzki, 95-050, Poland.
Dagmara GrotDepartment of Research and Development, Personather, LTD, Inwestycyjna 7 St, Konstantynow Lodzki, 95-050, Poland.
Pawel GlowackiDepartment of Research and Development, Personather, LTD, Inwestycyjna 7 St, Konstantynow Lodzki, 95-050, Poland.
Ewelina Stoczynska-Fidelus *Department of Research and Development, Personather, LTD, Inwestycyjna 7 St, Konstantynow Lodzki, 95-050, Poland.
Piotr Rieske *Department of Research and Development, Personather, LTD, Inwestycyjna 7 St, Konstantynow Lodzki, 95-050, Poland.

Funding

National Centre for Research and Development POIR.01.02.00-00-0034/15
6 · The paper itself

Abstract

backgroundSmall-molecule compounds that even partially restore the GTPase activity of RAS

methodsThe compounds were initially identified through virtual screening, and their optimal binding conformation in the RAS SW-II pocket was determined using the flexible docking technique. Efficacy was verified based on the IC50 determination, GTPase activity, as well as the AKT and ERK phospho WB assays.

resultsThe IC50 of the tested compounds was significantly lower against cells with the RAS

conclusionsWe have demonstrated molecules that partially restore the GTPase activity of RAS

Indexed as

Antineoplastic AgentsGTP Phosphohydrolasesras ProteinsSmall Molecule LibrariesCell Line, TumorHumansMolecular Docking SimulationMutationProto-Oncogene Proteins c-aktSignal TransductionAntineoplastic AgentsGTP PhosphohydrolasesProto-Oncogene Proteins c-aktras ProteinsSmall Molecule LibrariesColorectal cancerGTPaseLung cancerPancreatic cancerRASSmall moleculeTherapy

Identifiers

PMID39891136
PMCPMC11783748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.